Viewing Study NCT06505031



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06505031
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-07-11

Brief Title: A Study of TAK-861in People With Narcolepsy Type 1
Sponsor: None
Organization: None

Study Overview

Official Title: A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy Narcolepsy Type 1
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day called excessive daytime sleepiness or EDS after 3 months of treatment Other aims are to learn how effective TAK-861 is in lowering the number of sudden unexpected attacks of muscle weakness while staying conscious cataplexy in a week to learn the effect TAK-861 has on participants ability to maintain attention participants overall quality of life the spectrum of narcolepsy symptoms and daily life functions and to learn about the safety of TAK-861
Detailed Description: The drug being tested in this study is called TAK-861 TAK-861 is being tested to evaluate its efficacy and safety in participants with narcolepsy with cataplexy narcolepsy type 1 NT1

The study will enroll approximately 93 participants Participants will be randomly assigned by chance like flipping a coin to one of the two treatment groups

1 TAK-861
2 Placebo

The study drug will be administered for 12 weeks This multi-center trial will be conducted globally

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None